ORIGENIS

Origenis was founded in October 2005 through a management buy-out of former Morphochem AG's technology platform. Michael Almstetter, Dr. Michael Thormann, and Dr. Andreas Treml decided to continue their research programmes together with the drug discovery team they had built up. Two collaboration partners, Probiodrug (now Vivoryon) in the CNS field, and Alcon in the Ophthalmology fields supported this decision with continued trust and financial support. Both collaborations sought small molecules that would show sufficient exposure at the target tissue, passing through barriers that the brain and the eye have perfected to protect themselves... Our synergistic small molecule drug pipelines are either target-centric or disease-centric, or organ-centric. We pursue for example highly selective protein kinase inhibitors or protease inhibitors that are pivotal for a wide range of diseases and conditions. We focus on small molecule drugs that we design to select targets with high potency and..

Also known as: origenis gmbh

Registration numbers: HRB 158552 (W)

VAT numbers: DE814518112

Primary location: Martinsried Germany